



ImmusanT to Present at the 2018 BIO CEO & Investor Conference

CAMBRIDGE, Mass. – February 6, 2018 – [ImmusanT, Inc.](#), a clinical-stage company developing Nexvax2®, a therapeutic vaccine designed to protect patients with celiac disease against exposure to gluten and ultimately restore immune tolerance in celiac disease, today announced that Leslie Williams, Chief Executive Officer, will present at the 2018 BIO CEO & Investor Conference, occurring February 12-13, 2018 at the New York Marriott Marquis in New York City.

ImmusanT's presentation, which will provide an update on the company's clinical and business objectives, will take place at 11:15am ET on Monday, February 12 in the Gilbert Room.

About ImmusanT, Inc.

ImmusanT is a privately held biotechnology company focused on protecting patients with celiac disease against the effects of gluten. By harnessing new discoveries in immunology, ImmusanT aims to improve diagnosis and medical management of celiac disease by protecting against the effects of gluten exposure while patients maintain a gluten-free diet. The company is developing [Nexvax2®](#), a therapeutic vaccine for celiac disease, and diagnostic and monitoring tools to improve celiac disease management. ImmusanT's targeted immunotherapy discovery platform can be applied to a variety of autoimmune diseases. To learn more about ImmusanT, visit www.ImmusanT.com, or follow [ImmusanT](#) on Twitter.

ImmusanT Contact:

Leslie Williams
President and CEO
(617) 299-8399 Ext. 201
Leslie@ImmusanT.com

Media Contact:

George E. MacDougall
MacDougall Biomedical Communications
(781) 235-3093
george@macbiocom.com

###